Torque Therapeutics, Inc.

2024年4月29日，Repertoire Immune Medicines宣布与百时美施贵宝（BMS）达成战略合作，开发针对多达3种自身免疫性疾病的耐受疫苗。BMS将向Repertoire支付6500万美元的预付款，以及高达18亿美元的开发、监管和商业里程碑付款。根据协议，Repertoire将负责领导所有关于疫苗的活动，直至开发提名阶段，候选药物被BMS选中。而BMS则将在全球范围内获得耐受性疫苗许可，负责其临床开发、监管事务和商业化工作。Repertoire成立于2020年，位于美国马萨诸塞州，致力于T细胞创新疗法开发，以预防、治疗或治愈癌症、自身免疫病和传染病。该公司由知名生物医药投资机构Flagship Pioneering孵化的两家初创公司Cogen Immune Medicines和Torque Therapeutics合并后成立。其中，Cogen致力于研究破译T细胞免疫突触（immune synapse）的技术，而Torque则致力于创新抗癌疗法的开发。通过融合两家公司的技术平台，Repertoire可以从健康或病变的组织中破译人体中抗原和T细胞受体（TCR）之间的相互作用。具体来说，该公司的DECODE平台可发现引起疾病的抗原以及识别这些抗原的T细胞，而DEPLOY平台则能够够创建具有针对性的免疫药物，这些药物利用高特异性T细胞免疫靶向并清楚疾病。其中，DECODE平台能够绘制免疫突触的全貌，以分析TCR如何识别与其对应的独特抗原，通过分析得到的不是预测性表位抗原，而是可以与TCR结合的真正表位抗原。据Repertoire表示，本次与BMS的交易就将使用其DECODE平台来寻找候选疫苗。BMS免疫学和心血管主题研究中心负责人Francisco Ramírez-Valle在一份声明中表示，“我们与Repertoire的合作旨在选择性地重置免疫系统，反映了我们免疫学研究策略的一个关键组成部分，我们认为这可能会提供长期益处，同时减轻与广泛免疫抑制相关的意外后果。”BMS最近在交易领域一直很活跃。4月22日，百时美施贵宝BMS与制造商 Cellares 签订全球产能预订和供应协议，以加强公司的CAR-T细胞疗法生产。作为回报，Cellares 将获得总额高达 3.8 亿美元，折合人民币27.5亿元（1美元=4.2411人民币）的预付款和里程碑付款。回看过去6个月，BMS还先后收购了Karuna Therapeutics（140 亿美元）、RayzeBio（ 41 亿美元） 和Mirati Therapeutics（48 亿美元）。实际上，4月25日，BMS在其2024年第一季度的财报中表示，将实施一项全面的“战略生产力计划”，该计划包括组织管理结构重组和优化产品管线。这项举措旨在到2025年底节省约15亿美元，预计裁员6%，影响约2200名员工。而本次合作应该也是其优化管线的一环。附录：BMS最新管线一览参考资料：[1]BMS, Repertoire Ink Potential $1.8B Deal to Find Vaccines for Autoimmune Diseases.BioSpace.Published: Apr 29, 2024 By Tyler Patchen.[2]千亿巨星Moderna缔造者Flagship Pioneering，今年将哪些潜力股纳入投资版图？.创鉴汇.2021-11-18.[3]3.8亿美元，BMS 与 Cellares 签订CAR-T 细胞疗法生产协议.药融圈.2024-04-24.[4]BMS关闭湾区细胞疗法中心！.MedTrend医趋势.2024-04-28.[5]Repertoire Immune Medicines官网、BMS 2024一季报材料.识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观点，不代表本站立场。

2024年4月29日，Repertoire Immune Medicines宣布与百时美施贵宝达成合作协议，开发针对3种自免疾病的“耐受疫苗”，百时美施贵宝支付6500万美元预付款，最高18亿美元里程碑金额，以及一定比例的销售分成。 Repertoire将利用其TCR表位发现平台DECODE，和LNP递送技术来开发自免疾病的耐受疫苗。 通过DECODE技术平台确定TCR表位以后，通过LNP递送编码相应表位的mRNA来治疗自免疾病。 Repertoire已经在开发针对一型糖尿病、多发性硬化症等自免疾病的耐受疫苗。 Repertoire由Flagship孵化，2020年由其孵化的两家公司Torque Therapeutics和Cogen Immune Medicines合并而来。目前自免疾病药物开发，多从细胞因子或免疫细胞的调节角度入手。Repertoire的思路则是从引起自免反应的T细胞表位入手，用类似于过敏原脱敏的方式来治疗自免疾病，理论上更具有特异性。不过显而易见，这种治疗方式也存在极大的挑战，过敏疾病本质上可以看做一种特异性极强（过敏原高度特异）的自免疾病，而一般的自免疾病实际上是高度异质性的，不仅仅涉及诸多免疫细胞和细胞因子，T细胞表位理论上也会具有很大的异质性。针对不同的自免疾病，能否找到疗效足够好的T细胞表位存在很多挑战。尽管如此，如果看到肿瘤新抗原疫苗（本质上也是希望锁定一组几十个个性化的T细胞表位，来激活肿瘤特异性的T细胞）的发展历程，从多肽疫苗多年探索到mRNA的阶段性突破，相信自免疾病的治疗也存在类似的想象空间。 内容来源于网络，如有侵权，请联系删除。

Appointment of John Hohneker, M.D. Resignation of Chidozie Ugwumba PHILADELPHIA, April 1, 2024 /PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma" or the "Company"), a clinical-stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced the appointment of John Hohneker, M.D. to the Board of Directors of the Company, effective April 1, 2024. Additionally, the Company announced that Chidozie Ugwumba, who has served on Carisma's Board of Directors since December 2020, has advised the Board of his intent to step down from his role as a member of the Board and chair of the Audit Committee of the Board effective April 1, 2024, as a result of his other professional commitments. "We are pleased to welcome John to the Carisma Board of Directors," said Sanford Zweifach, Chair of the Carisma Board of Directors. "I believe John's extensive track record of clinical development, strategic leadership, and public company Board membership in the biopharmaceutical space will enable him to immediately support the Company as it continues leading the field of engineered macrophage development. We would also like to thank Chidozie for his invaluable advice and guidance since he first joined the Board over three years ago." "I am excited to join Carisma's Board as the Company continues to develop innovative immunotherapies," said Dr. Hohneker. "I am looking forward to partnering with the Board and the management team as they work to potentially bring novel treatments to patients in need across multiple therapeutic areas." Dr. Hohneker brings over 30 years of extensive experience in drug development and leadership across the biotech and pharmaceutical sectors. He most recently served as President and Chief Executive Officer of Anokion SA. Prior to this, he held the role of President of Research and Development at FORMA Therapeutics Inc. Before joining FORMA Therapeutics, Dr. Hohneker held roles of increasing responsibility at Novartis AG, including most recently as Senior Vice President and Global Head of Development, Immunology, and Dermatology. Prior to his time at Novartis, Dr. Hohneker held positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome. Dr. Hohneker currently serves on the Board of Directors of Curis, Inc., Sonata Therapeutics, Inc., and Trishula Therapeutics, Inc. Previously, Dr. Hohneker has served as a member of the Board of Directors of Torque Therapeutics, Inc., Dimension Therapeutics, Inc., Cygnal Therapeutics, Inc., BioTheryX Inc., Evelo Biosciences, Inc., Humanigen, Inc. and Aravive, Inc. Dr. Hohneker received his bachelor's degree in chemistry from Gettysburg College and his M.D. from the Rutgers School of Biomedical and Health Sciences (formerly the University of Medicine and Dentistry of New Jersey-Rutgers Medical School). He completed his internship and residency in internal medicine and his fellowship in medical oncology, all at the University of North Carolina at Chapel Hill. About Carisma Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on utilizing our proprietary macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. We have created a comprehensive, differentiated proprietary cell therapy platform focused on engineered macrophages and monocytes, cells that play a crucial role in both the innate and adaptive immune response. Carisma is headquartered in Philadelphia, PA. For more information, please visit . Investors: Shveta Dighe Head of Investor Relations investors@carismatx.com Company Codes: NASDAQ-NMS:CARM